-
[show abstract]
[hide abstract]
ABSTRACT: Some semi-synthetic derivatives of glycopeptide antibiotics have been shown to exert in vitro antiviral activity against HIV and coronaviruses. Here we report and characterize the in vitro anti-hepatitis C virus (HCV) activity of several semi-synthetic derivatives of teicoplanin aglycone.
Anti-HCV activity was analysed in: (i) three different subgenomic HCV replicon systems using a luciferase or quantitative RT-PCR (qRT-PCR) assay; and (ii) an infectious HCV cell culture system by means of qRT-PCR and immunofluorescence assays.
Several teicoplanin aglycone derivatives elicited selective anti-HCV activity in replicons as well as infectious cell culture systems, with LCTA-949 being the most potent derivative. LCTA-949 proved, in contrast to several directly acting antivirals for HCV, efficient in clearing cells of their replicons. When LCTA-949 was combined with HCV protease or polymerase inhibitors an overall additive effect was observed. Likewise, LCTA-949 was equipotent against wild-type replicons as well as against replicons resistant to polymerase and protease inhibitors. Following up to 4 months of selective pressure, no drug-resistant replicons were selected. When combined with the HCV NS3 protease inhibitor VX-950, LCTA-949 prevented the development of VX-950-resistant variants.
Semi-synthetic derivatives of teicoplanin aglycone constitute a novel class of HCV replication inhibitors that are not cross-resistant with various HCV protease and polymerase inhibitors and in particular are potent in clearing hepatoma cells of their replicons. This class of molecules also provides a good tool to obtain novel insights into the replication cycle of HCV and into cellular factors/processes that are crucial for viral replication.
Journal of Antimicrobial Chemotherapy 03/2011; 66(6):1287-94. · 5.07 Impact Factor
-
Maria N Preobrazhenskaya,
Eugenia N Olsufyeva,
Anna N Tevyashova, Svetlana S Printsevskaya,
Svetlana E Solovieva,
Marina I Reznikova,
Aleksey S Trenin,
Olga A Galatenko,
Ivan D Treshalin,
Eleonora R Pereverzeva,
Elena P Mirchink,
Sergey B Zotchev
[show abstract]
[hide abstract]
ABSTRACT: Mono- and disubstituted novel derivatives of the heptaene nystatin analog 28,29-didehydronystatin A(1) (S44HP, 1) were obtained by chemical modification of the exocyclic C-16 carboxyl and/or an amino group of mycosamine moiety. The strategy of preparation of mono- and double-modified polyene macrolides was based on the use of intermediate hydrophobic N-Fmoc (9-fluorenylmethoxycarbonyl) derivatives that facilitated the procedures of isolation and purification of new compounds. The antifungal activity of the new derivatives was first tested in vitro against yeasts and filamentous fungi, allowing the selection of the most active compounds that were subsequently tested for acute toxicity in mice. 2-(N,N-dimethylamino)ethylamide of 1 (2) and 2-(N,N-dimethylamino)ethylamide of N-fructopyranosyl-28,29-didehydronystatin A(1) (2a) were then selected for further evaluation in a mouse model of disseminated candidosis, and showed high efficacy while being considerably less toxic than amphotericin B (AmB). The compound with improved water solubility (2G, L-glutamic acid salt of 2) showed better chemotherapeutic activity than AmB in the mouse model of candidosis sepsis on a leucopenic background. Very low antifungal effect was seen after treatment with AmB, even if it was used in maximum tolerated dose (2 mg kg(-1)). Unlike AmB, compound 2G exhibited high activity in doses from 0.4 up to 4.0 mg kg(-1), despite leucopenic conditions.
The Journal of Antibiotics 12/2009; 63(2):55-64. · 1.65 Impact Factor
-
Valery N Danilenko,
Alexander Y Simonov,
Sergey A Lakatosh,
Michael H G Kubbutat,
Frank Totzke,
Christoph Schächtele,
Sergey M Elizarov,
Olga B Bekker, Svetlana S Printsevskaya,
Yuryi N Luzikov,
Marina I Reznikova,
Alexander A Shtil,
Maria N Preobrazhenskaya
[show abstract]
[hide abstract]
ABSTRACT: Aminomethylation of 9b,10-dihydro-1H-indolo[1,7:4,5,6]pyrrolo[3,4:2,3][1,4]diazepino-[1,7-a]indole-1,3(2H)-diones or 1H-indolo[1,7:4,5,6]pyrrolo[3,4:2,3][1,4]diazepino[1,7-a]indole-1,3(2H)-diones resulted in dialkylaminomethyl derivatives. Alkylation of the nitrogen atom of maleimide moiety of polyannelated diazepines with 1,3-dibromopropane and subsequent reaction with thiourea or its N-alkyl derivatives gave isothiourea-carrying compounds. The compounds containing isothiourea moiety were active against individual human serine/threonine and tyrosine kinases at low micromolar concentrations. Dialkylaminomethyl derivatives of diazepines sensitized Streptomyces lividans with overexpressed aminoglycoside phosphotransferase type VIII (aphVIII) to kanamycin by inhibiting serine/threonine kinase(s) mediated aphVIII phosphorylation.
Journal of Medicinal Chemistry 01/2009; 51(24):7731-6. · 4.80 Impact Factor
-
Kirk R Maples,
Conrad Wheeler,
Emily Ip,
Jacob J Plattner,
Daniel Chu,
Yong-Kang Zhang,
Maria N Preobrazhenskaya, Svetlana S Printsevskaya,
Svetlana E Solovieva,
Evgenia N Olsufyeva,
Henry Heine,
Julie Lovchik,
C Richard Lyons
[show abstract]
[hide abstract]
ABSTRACT: Five adamantyl-containing carboxamides of eremomycin or vancomycin were synthesized and their antibacterial activities against some Gram-positive clinical isolates were investigated in vitro and in vivo. The adamantyl-2 amide of glycopeptide antibiotic eremomycin (1a in Chart 1, AN0900) was the most active compound and showed high activity against several Gram-positive pathogens: vancomycin-susceptible staphylococci and enterococci, glycopeptide-intermediate-resistant Staphylococcus aureus, and glycopeptide-resistant enterococci. Compound 1a was equally active in vitro against both Ciprofloxacin-susceptible and -resistant Bacillus anthracis strains (MICs 0.25-0.5 microg/mL). It was distinguished by having a 2.8 h half-life (t1/2) in mice and a volume of distribution of 2.18 L/kg. Compound 1a was active against Staphylococcus aureus in mice (iv) and provided complete protection against a lethal intravenous challenge with vegetative B. anthracis bacilli and also in a murine pulmonary anthrax model in which mice were challenged with Bacillus anthracis spores.
Journal of Medicinal Chemistry 08/2007; 50(15):3681-5. · 5.25 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The acylation of unprotected vancomycin or eremomycin with activated esters of N(alpha)-protected amino acids or N(alpha)-alkyl-N(alpha)-Fmoc-amino acids is directed selectively to the amino group of the disaccharide branch (N') and after Fmoc-group removal leads to the corresponding N'-alpha-aminoacyl derivatives. A series of N'-alpha-aminoacyl and N'-alpha-(N(alpha)-alkylamino)acyl derivatives of eremomycin and vancomycin containing hydrophobic moieties has been synthesized. The structures of all derivatives were confirmed by Electrospray Ionization mass-spectral (ESI MS) analysis, and by chemical degradation methods. Position of the introduced N'-alpha-aminoacyl- and N-(N(alpha)-alkylamino)acyl groups were determined after Edman degradation and acidic hydrolysis. The structures of the synthesized starting reagents (N(alpha)-alkylamino acids or N(alpha)-alkyl-N(alpha)-Fmocamino acids) were confirmed by NMR-spectra data. In general, N'-(N-alkylglycyl)-derivatives were more active than the corresponding N'-alpha-(N(alpha)-alkylamino)acylated derivatives containing other amino acids (L-Lys, L-Met, L-Orn, L- and D-Ala, L- and D-Phe and benzyl-O-L-Tyr).
The Journal of Antibiotics 05/2007; 60(4):235-44. · 1.65 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The antibacterial activities of the series of novel N'-(alpha-aminoacyl)- and N'-alpha-(N-akylamino)acyl derivatives of eremomycin and vancomycin containing hydrophobic moieties have been investigated. The N'-(N-alkylglycyl) derivatives of vancomycin are more active against vancomycin-susceptible staphylococci and enterococci and glycopeptide intermediate-resistant Staphylococcus aureus (GISA) than the corresponding eremomycin derivatives, but except for N'-[N-(p-octyloxybenzyl)glycyl-vancomycin] (28) and N'-[N-(p-octyloxybenzyl)-L-alanyl-vancomycin (33)--they are less active against glycopeptide-resistant enterococci (GRE). Derivatives 28 and 33 are the most active compounds (MIC's for glycopeptide-sensitive staphylococci and enterococci are 0.25 approximately 1 microg/ml, for GISA 1 approximately 2 microg/ml, for GRE 2 approximately 6 microg/ml). In in vivo studies, derivative 28 was active against S. aureus infections in mice with ED(50) 1 mg/kg versus 2 mg/kg for vancomycin (iv). In general N'-(N-alkylglycyl)-derivatives of vancomycin and eremomycin were more active than the corresponding N'-aminoacylated derivatives of these antibiotics containing other than glycin amino acids (L-Lys, L-Met, L-Orn, L- and D-Ala) and also L- and D-Phe or benzyl-O-L-Tyr.
The Journal of Antibiotics 05/2007; 60(4):245-50. · 1.65 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The acylation of unprotected vancomycin or eremomycin with activated esters of N-protected amino acids or N-alkyl-N-Fmoc-amino acids is directed selectively to the amino group of the disaccharide branch (N') and after Fmoc-group removal leads to the corresponding N'--aminoacyl derivatives. A series of N'--aminoacyl and N'--(N-alkylamino)acyl derivatives of eremomycin and vancomycin containing hydrophobic moieties has been synthesized. The structures of all derivatives were confirmed by Electrospray Ionization mass-spectral (ESI MS) analysis, and by chemical degradation methods. Position of the introduced N'--aminoacyl- and N-(N-alkylamino)acyl groups were determined after Edman degradation and acidic hydrolysis.The structures of the synthesized starting reagents (N-alkylamino acids or N-alkyl-N-Fmocamino acids) were confirmed by NMR-spectra data. In general, N'-(N-alkylglycyl)-derivatives were more active than the corresponding N'--(N-alkylamino)acylated derivatives containing other amino acids (L-Lys, L-Met, L-Orn, L- and D-Ala, L- and D-Phe and benzyl-O-L-Tyr).Keywords: vancomycin, eremomycin, antibacterial, semisynthetic derivatives, selective acylation
The Journal of Antibiotics 03/2007; 60(4):235-244. · 1.65 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Various semisynthetic derivatives of glycopeptide antibiotics including vancomycin, eremomycin, teicoplanin, ristocetin A and DA-40926 have been evaluated for their inhibitory activity against feline infectious peritonitis virus (FIPV) and human (SARS-CoV, Frankfurt-1 strain) coronavirus in cell culture in comparison with their activity against human immunodeficiency virus (HIV). Several glycopeptide derivatives modified with hydrophobic substituents showed selective antiviral activity. For the most active compounds, the 50% effective concentrations (EC(50)) were in the lower micromolar range. In general, removal of the carbohydrate parts of the molecules did not affect the antiviral activity of the compounds. Some compounds showed inhibitory activity against both, whereas other compounds proved inhibitory to either, FIPV or SARS-CoV. There was no close correlation between the EC(50) values of the glycopeptide derivatives for FIPV or SARS-CoV.
Antiviral Research 11/2006; 72(1):20-33. · 4.30 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: N-(adamantyl-1)methyl, N-(adamantyl-2), and N-(omega-aminodecyl) amides of vancomycin, eremomycin, and dechloroeremomycin aglycons and their des-(N-Me-D-Leu) derivatives were synthesized and their antibacterial and anti-HIV activities were investigated. Carboxamides with an intact peptide core demonstrated activity against glycopeptide-susceptible and -resistant bacteria (1-32 microM). N-(adamantyl-1)methylcarboxamide of eremomycin aglycons had good antiretroviral activity (1.6 microM against HIV-1). Compounds with destroyed peptide core [des-(N-Me-D-Leu)-aglycon amides] were inactive against both glycopeptide-sensitive and -resistant bacteria. (Adamantyl-1)methylamide of des-(N-Me-D-Leu)-eremomycin aglycon had good antiretroviral activity (EC50 of 5.5 microM for HIV-1 and 3.5 microM for HIV-2). (Adamantyl-1)methylamides of eremomycin aglycon and its des-(N-Me-d-Leu)-derivative are the most promising and selective antiretroviral agents. Their ability to induce bacterial resistance to glycopeptide antibiotics during prolonged administration may be expected to be very low or absent. This might make the use of these derivatives feasible in the prolonged therapy or prophylaxis of HIV infections.
Journal of Medicinal Chemistry 07/2005; 48(11):3885-90. · 5.25 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: A variety of semisynthetic derivatives of natural antibacterial glycopeptide antibiotics such as vancomycin, eremomycin, ristocetin A, teicoplanin A(2)-2, DA-40926, their aglycons, and also the products of their partial degradation with a destroyed or modified peptide core show marked anti-retroviral activity in cell culture. In particular, aglycon antibiotic derivatives containing various substituents of a preferably hydrophobic nature displayed activity against human immunodeficiency virus type 1 (HIV-1), HIV-2, and Moloney murine sarcoma virus at a 50% inhibitory concentration in the lower micromolar (1-5 microM) concentration range while not being cytostatic against human lymphocytic cells at 250 microM or higher. The mode of anti-HIV action of the antibiotic aglycon derivatives could be ascribed to inhibition of the viral entry process.
Journal of Medicinal Chemistry 07/2003; 46(13):2755-64. · 5.25 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The antibacterial properties of glycopeptide antibiotics are based on their interaction with the d-Ala-d-Ala containing pentapeptide of bacterial peptidoglycan. The hydrophobic amides of vancomycin (1), teicoplanin (2), teicoplanin aglycon (3), and eremomycin (4) were compared with similar amides of minimally or low active des-(N-methyl-d-leucyl)eremomycin (5), eremomycin aglycon (6), des-(N-methyl-d-leucyl)eremomycin aglycon (7), and a teicoplanin degradation product TB-TPA (8). All hydrophobic amides of 1, 3, 4, and 6 were almost equally active against glycopeptide-resistant enterococci (GRE) [minimum inhibitory concentrations (MIC) <or= 4 microg/mL] and had better activity against Gram-positive strains sensitive to glycopeptides than against GRE. Extensive degradation of the glycopeptide framework in amides of 7 and 8 led to a decrease of anti-GRE activity (MIC = 16-64 microg/mL), and for these derivatives MIC values for bacterial strains sensitive and resistant to glycopeptides were very close. These results suggest that in sensitive bacteria two mechanisms of action are operating for the hydrophobic derivatives of glycopeptide antibiotics with the nondamaged peptide core-interaction with the d-Ala-d-Ala moiety and the inhibition of bacterial membrane bound enzymatic reactions, whereas for GRE lacking the d-Ala-d-Ala fragment, only the second mechanism is operating. It appears that a minimal glycopeptide core is required for activity, and that more extensive degradation results in a serious decrease of antibacterial activity.
Journal of Medicinal Chemistry 03/2003; 46(7):1204-9. · 5.25 Impact Factor
-
Svetlana S Printsevskaya,
Andrey Y Pavlov,
Evgenia N Olsufyeva,
Elena P Mirchink,
Elena B Isakova,
Marina I Reznikova,
Robert C Goldman,
Arthur A Branstrom,
Eugene R Baizman,
Clifford B Longley,
Ferenc Sztaricskai,
Gyula Batta,
Maria N Preobrazhenskaya
[show abstract]
[hide abstract]
ABSTRACT: Des-(N-methyl-D-leucyl)eremomycin was obtained by Edman degradation of eremomycin. Derivatives with a hydrophobic substituent at the exterior of the molecule were then synthesized, and their antibacterial activities were compared with similar derivatives of eremomycin. Comparison of derivatives of eremomycin containing the n-decyl or p-(p-chlorophenyl)benzyl substituent in the eremosamine moiety (N') and n-decyl or p-(p-chlorophenyl)benzylamides with similar derivatives of eremomycin possessing the damaged peptide core (a defective binding pocket) showed that compounds of both types are almost equally active against glycopeptide-resistant strains of enterococci (GRE), whereas eremomycin derivatives are more active against staphylococci. Hydrophobic 7d-alkylaminomethylated derivatives of eremomycin (9, 10) demonstrated similar antibacterial properties. Since the basic mode of action of glycopeptide antibiotics involves binding to cell wall intermediates terminating in -D-Ala-D-Ala and this interaction is seriously decreased in the hexapeptide derivatives (lacking the critical N-methyl-D-leucine), we suggest that these hydrophobic derivatives may inhibit peptidoglycan synthesis in the absence of dipeptide binding. NMR binding experiments using Ac-D-Ala-D-Ala show that binding constants of these hexapeptide derivativies are decreased in comparison with the corresponding heptapeptides with intact binding pocket. This is in agreement with the decreased biological activity of the hexapeptide derivatives against vancomycin-sensitive strains in comparison with the activity of parent compounds. Binding to the lactate cell wall analogue Ac-D-Ala-D-Lac with decylamide of eremomycin 8 was not observed, demonstrating that the interaction with this target in GRE does not occur. While hydrophobic glycopeptide derivatives retain the ability to inhibit the synthesis of peptidoglycan in manner of natural glycopeptides, biochemical investigation supports the hypothesis that they inhibit the transglycosylase stage of bacterial peptidoglycan biosynthesis even in the absence of dipeptide or depsipeptide binding.
Journal of Medicinal Chemistry 04/2002; 45(6):1340-7. · 5.25 Impact Factor
